IL-22 R alpha 1 Overview
Molecule Name
Interleukin-22 receptor
Drug Development Progress
Drugs in Clinical Trials5
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Background
Interleukin-22 receptor subunit alpha-1(IL22RA1) is a component of the receptor for IL20, IL22 and IL24.Component of IL22 receptor formed by IL22RA1 and IL10RB enabling IL22 signaling via JAK/STAT pathways. IL22 also induces activation of MAPK1/MAPK3 and Akt kinases pathways. Component of one of the receptor for IL20 and IL24 formed by IL22RA1 and IL20RB also signaling through STATs activation. Mediates IL24 antiangiogenic activity as well as IL24 inhibitory effect on endothelial cell tube formation and differentiation.
IL-22 R alpha 1 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Efmarodocokin alfa | RO-7021610; UTTR-1147A; RG-7880 | Phase 2 Clinical | Genentech Inc | Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Diabetic Foot; Graft vs Host Disease | Details |
| Temtokibart | ARGX-112; LEO-138559; LP-0145 | Phase 2 Clinical | Argenx Se, Leo Pharma Inc | Dermatitis, Atopic | Details |
| CK-0045 | CK-0045 | Phase 2 Clinical | Cytoki Pharma ApS | Diabetes Mellitus, Type 2; Obesity; Overweight | Details |
| Eflepedocokin alfa | F-652 | Phase 2 Clinical | Evive Biotech Ltd | Acute-On-Chronic Liver Failure; Coronavirus Disease 2019 (COVID-19); Enteritis; Enterocolitis, Necrotizing; Graft vs Host Disease; Hepatitis, Alcoholic; Pancreatitis | Details |
| ABBV-022 | ABBV-022 | Phase 1 Clinical | Abbvie Inc | Colitis, Ulcerative | Details |